Could a repurposed drug boost immune attack on childhood brain tumors?

This early-phase trial is testing whether adding the drug ibrutinib to a chemo-immunotherapy regimen can safely help children and young adults (ages 6–25) with brain cancers that have come back or not responded to standard treatment. The study combines ibrutinib with indoximod and two chemotherapy drugs to try to boost the immune system's ability to fight the tumor. The main goals are to find the best safe dose and to see if the combination shrinks tumors.